Prostate cancer study tests if newer drug reduces unwanted side effects
NCT ID NCT05526248
Summary
This study compared two prostate cancer drugs, darolutamide and enzalutamide, to see if one causes fewer side effects like breast tenderness and tissue growth. Researchers tested 28 men whose prostate cancer had returned after initial treatment but hadn't spread significantly. They measured how each drug affected testosterone levels over a year, since higher testosterone is linked to these specific side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center - Oncology
Boston, Massachusetts, 02215, United States
-
Central Ohio Urology Group - Gahanna
Gahanna, Ohio, 43230, United States
-
Mass General Cancer Center
Boston, Massachusetts, 02114-2696, United States
-
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York, 10065, United States
-
Unio Specialty Care - Urology - Sherman Oaks
Sherman Oaks, California, 91411, United States
Conditions
Explore the condition pages connected to this study.